MA41176A - Complexes radio-pharmaceutiques - Google Patents

Complexes radio-pharmaceutiques

Info

Publication number: MA41176A
Authority: MA; Morocco
Prior art keywords: radio; pharmaceutical complexes; complexes; pharmaceutical
Prior art date: 2014-12-17

Application number

MA041176A

Other languages

English (en)

Inventor

Alan Cuthbertson

Original Assignee

Bayer As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-12-17

Filing date

2015-12-14

Publication date

2017-10-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54884033&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA41176(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-12-14 Application filed by Bayer As filed Critical Bayer As

2017-10-24 Publication of MA41176A publication Critical patent/MA41176A/fr

Links

229940121896 radiopharmaceutical Drugs 0.000 title 1
239000012217 radiopharmaceutical Substances 0.000 title 1
230000002799 radiopharmaceutical effect Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1021—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against cytokines, e.g. growth factors, VEGF, TNF, lymphokines or interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
- A61K51/103—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for growth factors or receptors for growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Optics & Photonics (AREA)
Physics & Mathematics (AREA)
Epidemiology (AREA)
Immunology (AREA)
Oncology (AREA)
Cell Biology (AREA)
Hematology (AREA)
Reproductive Health (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pyridine Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

MA041176A 2014-12-17 2015-12-14 Complexes radio-pharmaceutiques MA41176A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB201422512		2014-12-17

Publications (1)

Publication Number	Publication Date
MA41176A true MA41176A (fr)	2017-10-24

Family

ID=54884033

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA041176A MA41176A (fr)	2014-12-17	2015-12-14	Complexes radio-pharmaceutiques

Country Status (30)

Country	Link
US (2)	US20170340759A1 (fr)
EP (1)	EP3233137A1 (fr)
JP (2)	JP6821569B2 (fr)
KR (1)	KR20170094223A (fr)
CN (1)	CN107278155B (fr)
AR (1)	AR103063A1 (fr)
AU (2)	AU2015367722A1 (fr)
BR (1)	BR112017012841A2 (fr)
CA (1)	CA2970841A1 (fr)
CL (1)	CL2017001592A1 (fr)
CO (1)	CO2017005975A2 (fr)
CR (1)	CR20170256A (fr)
CU (1)	CU24493B1 (fr)
DO (1)	DOP2017000143A (fr)
EA (1)	EA201791350A9 (fr)
EC (1)	ECSP17038089A (fr)
IL (1)	IL252244B (fr)
JO (1)	JOP20150319B1 (fr)
MA (1)	MA41176A (fr)
MX (1)	MX384088B (fr)
MY (1)	MY194190A (fr)
NI (1)	NI201700076A (fr)
PE (2)	PE20230829A1 (fr)
PH (1)	PH12017501125A1 (fr)
SG (1)	SG11201704917XA (fr)
TN (1)	TN2017000255A1 (fr)
TW (1)	TWI654179B (fr)
UA (1)	UA125369C2 (fr)
UY (1)	UY36453A (fr)
WO (1)	WO2016096843A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3432936A1 (fr)	2016-03-24	2019-01-30	Bayer Pharma Aktiengesellschaft	Complexes radiopharmaceutiques
CR20180581A (es) *	2016-06-10	2019-02-11	Bayer Pharma AG	Complejos radio-farmacéuticos
WO2018153975A1 (fr)	2017-02-24	2018-08-30	Bayer As	Polythérapie comprenant un agent radiopharmaceutique et un inhibiteur de réparation d'adn
ES2992988T3 (en)	2017-03-30	2024-12-20	Univ Cornell	Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer
US20210187134A1 (en)	2018-08-28	2021-06-24	Bayer As	Combination of pi3k-inhibitors and targeted thorium conjugates
WO2020169537A1 (fr)	2019-02-21	2020-08-27	Bayer Aktiengesellschaft	Combinaison d'inhibiteurs pd-1/pd-l1 et de conjugués de thorium ciblés
WO2020169538A1 (fr)	2019-02-22	2020-08-27	Bayer Aktiengesellschaft	Combinaison d'antagonistes de l'ar et de conjugués de thorium ciblés
AR119479A1 (es)	2019-07-25	2021-12-22	Bayer As	Radiofármacos dirigidos para diagnóstico y tratamiento de cáncer
TW202216771A (zh)	2020-06-26	2022-05-01	德商拜耳廠股份有限公司	用於治療應用之ccr8抗體
CN116745323A (zh)	2021-01-22	2023-09-12	拜耳股份有限公司	Lrrc15抗体及其缀合物
JPWO2025058000A1 (fr)	2023-09-13	2025-03-20

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8158804B2 (en) *	2007-01-11	2012-04-17	Ge Healthcare As	Chelating agents
GB201002508D0 (en) *	2010-02-12	2010-03-31	Algeta As	Product
GB201208309D0 (en) *	2012-05-11	2012-06-27	Algeta As	Complexes

2015
- 2015-12-14 MA MA041176A patent/MA41176A/fr unknown
- 2015-12-15 CR CR20170256A patent/CR20170256A/es unknown
- 2015-12-15 EA EA201791350A patent/EA201791350A9/ru unknown
- 2015-12-15 MY MYPI2017702228A patent/MY194190A/en unknown
- 2015-12-15 MX MX2017008093A patent/MX384088B/es unknown
- 2015-12-15 CA CA2970841A patent/CA2970841A1/fr active Pending
- 2015-12-15 WO PCT/EP2015/079773 patent/WO2016096843A1/fr not_active Ceased
- 2015-12-15 TN TN2017000255A patent/TN2017000255A1/en unknown
- 2015-12-15 PE PE2022002504A patent/PE20230829A1/es unknown
- 2015-12-15 JP JP2017532833A patent/JP6821569B2/ja active Active
- 2015-12-15 KR KR1020177016311A patent/KR20170094223A/ko not_active Withdrawn
- 2015-12-15 BR BR112017012841A patent/BR112017012841A2/pt not_active Application Discontinuation
- 2015-12-15 AU AU2015367722A patent/AU2015367722A1/en not_active Abandoned
- 2015-12-15 CU CU2017000082A patent/CU24493B1/es unknown
- 2015-12-15 EP EP15813024.5A patent/EP3233137A1/fr active Pending
- 2015-12-15 US US15/537,127 patent/US20170340759A1/en not_active Abandoned
- 2015-12-15 UA UAA201707516A patent/UA125369C2/uk unknown
- 2015-12-15 CN CN201580069545.0A patent/CN107278155B/zh active Active
- 2015-12-15 SG SG11201704917XA patent/SG11201704917XA/en unknown
- 2015-12-15 PE PE2017001093A patent/PE20171181A1/es unknown
- 2015-12-16 JO JOP/2015/0319A patent/JOP20150319B1/ar active
- 2015-12-17 TW TW104142567A patent/TWI654179B/zh active
- 2015-12-17 UY UY0001036453A patent/UY36453A/es not_active Application Discontinuation
- 2015-12-17 AR ARP150104130A patent/AR103063A1/es not_active Application Discontinuation
2017
- 2017-05-11 IL IL252244A patent/IL252244B/en active IP Right Grant
- 2017-06-15 PH PH12017501125A patent/PH12017501125A1/en unknown
- 2017-06-16 CL CL2017001592A patent/CL2017001592A1/es unknown
- 2017-06-16 DO DO2017000143A patent/DOP2017000143A/es unknown
- 2017-06-16 CO CONC2017/0005975A patent/CO2017005975A2/es unknown
- 2017-06-16 NI NI201700076A patent/NI201700076A/es unknown
- 2017-06-19 EC ECIEPI201738089A patent/ECSP17038089A/es unknown
2021
- 2021-01-05 JP JP2021000454A patent/JP7160961B2/ja active Active
- 2021-01-15 US US17/150,811 patent/US20210322583A1/en not_active Abandoned
- 2021-04-29 AU AU2021202665A patent/AU2021202665B2/en not_active Ceased

Also Published As

Publication number	Publication date
JOP20150319B1 (ar)	2021-08-17
JP2018506513A (ja)	2018-03-08
EP3233137A1 (fr)	2017-10-25
IL252244B (en)	2020-10-29
JP7160961B2 (ja)	2022-10-25
BR112017012841A2 (pt)	2018-04-10
CL2017001592A1 (es)	2018-03-16
PH12017501125A1 (en)	2017-11-27
EA201791350A9 (ru)	2020-02-11
NI201700076A (es)	2017-09-22
UY36453A (es)	2016-07-29
CA2970841A1 (fr)	2016-06-23
CO2017005975A2 (es)	2017-11-30
US20170340759A1 (en)	2017-11-30
JP2021063108A (ja)	2021-04-22
WO2016096843A1 (fr)	2016-06-23
SG11201704917XA (en)	2017-07-28
PE20230829A1 (es)	2023-05-19
TWI654179B (zh)	2019-03-21
MX2017008093A (es)	2018-02-09
US20210322583A1 (en)	2021-10-21
AU2015367722A1 (en)	2017-06-08
CN107278155B (zh)	2021-03-30
CU24493B1 (es)	2020-12-17
AU2021202665A1 (en)	2021-05-27
MY194190A (en)	2022-11-18
CR20170256A (es)	2017-08-11
IL252244A0 (en)	2017-07-31
EA201791350A1 (ru)	2017-12-29
KR20170094223A (ko)	2017-08-17
PE20171181A1 (es)	2017-08-22
DOP2017000143A (es)	2017-07-15
CN107278155A (zh)	2017-10-20
TN2017000255A1 (en)	2018-10-19
AR103063A1 (es)	2017-04-12
MX384088B (es)	2025-03-14
UA125369C2 (uk)	2022-03-02
CU20170082A7 (es)	2017-10-05
ECSP17038089A (es)	2017-07-31
TW201627286A (zh)	2016-08-01
AU2021202665B2 (en)	2023-04-27
JP6821569B2 (ja)	2021-01-27

Publication	Publication Date	Title
MA45225A (fr)	2019-04-17	Complexes radiopharmaceutiques
DK3240801T3 (da)	2021-02-08	Kombinationstumorimmunterapi
DK3215153T3 (da)	2021-03-22	Immunregulatoriske midler
DK3183051T3 (da)	2020-06-02	Væske-til-luftmembranenergivekslere
LT3134402T (lt)	2020-07-10	4-amino-imidazochinolino junginiai
DK3211743T3 (da)	2019-12-16	Ø-til-netværk-omskiftningsfremgangsmåde
FIC20265009I1 (fi)	2026-04-18	Brensocatib
DK3006072T3 (da)	2021-10-25	Karadgang
DK3222714T3 (da)	2019-12-09	Phytasemutanter
DK3119396T3 (da)	2021-05-31	Muscarinreceptoragonister
IL252244A0 (en)	2017-07-31	Radioactive pharmaceutical complexes
DK3183340T3 (da)	2019-08-19	Termolabile exonukleaser
BR112016030730A2 (pt)	2017-08-22	Composto
EP4546794C0 (fr)	2026-02-25	Concept de raccordement audio
DE112015001664A5 (de)	2016-12-29	Betätigungsaktuator
DK3154703T3 (da)	2020-11-16	Fuldkappe-snekkecentrifuge
DK3154689T3 (da)	2021-04-26	Komplekser
DE112015005041A5 (de)	2017-08-31	Gargerätevorrichtung
DK3191466T3 (da)	2020-01-20	Azetidinyloxyphenylpyrrolidinforbindelser
DK3110439T3 (da)	2019-05-13	Pcsk9-vacciner
DE102014000623A8 (de)	2016-10-13	Halbhohlnietelement
DK3154945T3 (da)	2021-06-28	Komplekser
DK3009858T3 (da)	2021-08-09	Skyradar
DE202014005655U8 (de)	2014-11-13	llluminationsvorrichtung
BR112016027901A2 (pt)	2017-08-22	Compostos